Maternal use of valproic acid (VPA) during pregnancy is associated with an increased risk of autism spectrum disorder (ASD) in the offspring. In the pathophysiological hypothesis of ASD, excitation/inhibition (E/I) imbalance is attracted. Dysfunction of serotonergic system is also suggested to be involved in ASD. In this study, we investigated glutamatergic-serotonergic neuronal interaction in the ASD-like behavior induced by prenatal VPA exposure in mice. Prenatal VPA exposure induced not only excessive repetitive self-grooming behavior, impairments of social behavior and object recognition memory, but also increased glutamatergic signaling (CaMKII phosphorylation) and decreased serotonin contents in the prefrontal cortex. Memantine (low-affinity NMDA antagonist) suppressed both the increase of CaMKII phosphorylation and ASD-like behaviors. Activation of serotonergic signaling via 5-HT_1A receptor by fluoxetine, tandospirone (5-HT_1A receptor agonist) and optogenetics attenuated the ASD-like behaviors in prenatal VPA-exposed mice. WAY-100635 (5-HT_1A receptor antagonist) antagonized the effect of fluoxetine on the ASD-like behaviors. These results suggest that the hyper-NMDA receptor signaling and ASD-like behaviors are associated with hypo-signaling of 5-HT_1A receptor in the prenatal VPA-exposed mice.